Skip to content

Clinical efficacy and brain network characteristics of neuronavigation transcranial magnetic stimulation in the treatment of negative symptoms in schizophrenia

Clinical efficacy and brain network characteristics of neuronavigation transcranial magnetic stimulation in the treatment of negative symptoms in schizophrenia

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300075311
Enrollment
Unknown
Registered
2023-09-01
Start date
2023-09-01
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Interventions

Group A:right medial superior frontal gyrus+drug treatment
Group B:left dorsolateral prefrontal cortex stimulation+drug treatment group
Group C:right medial superior frontal gyrus pseudo stimulation+drug treatment

Sponsors

The Second Affiliated Hospital of Xinxiang Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Outpatients or inpatients; 2. This episode meets the clinical diagnostic criteria for DSM-5 schizophrenia; 3. Age: 18-45 years old; Gender unlimited; Han Chinese; 4. PANSS score = 60 points; 5. Obtain written informed consent from the patient. If the patient is incapacitated or a minor during the onset of the disease, they must obtain written informed consent from their legal guardian; 6. Those who have no abnormal findings during physical examination; Vital signs, general physical examination, blood routine, urine routine, blood biochemistry, and electrocardiogram are all normal; 7. Those without contraindications to MRI scanning.

Exclusion criteria

Exclusion criteria: 1. Those whose physical examination does not meet the above subject standards; 2. Those who meet the DSM-5 diagnostic criteria for depression, schizophrenic affective disorder, mental developmental delay, generalized developmental disorder, delirium, dementia, memory impairment, or other cognitive impairments; 3. Those suffering from severe unstable physical diseases; 4. Diagnosed diabetes, thyroid disease, hypertension, heart disease, etc; 5. Narrow angle glaucoma; 6. Therapists with suicidal tendencies; Individuals with a history of epilepsy, excluding those with high fever seizures; 7. Patients who meet the DSM-5 diagnostic criteria for alcohol and drug dependence (excluding nicotine dependence); 8. Have used tDCS or rTMS three months before joining the group; 9. Those who have used ECT treatment in the first six months of enrollment; 10. Suffering from or having previously suffered from drug-induced malignant syndrome; 11. Those who suffer from or have previously suffered from drug-induced malignant syndrome or severe delayed motor disorders; 12. Pregnant or lactating women, or those planning to conceive; 13. Patients with head injury accompanied by consciousness disorders for more than 5 minutes; 14. Contraindications to magnetic resonance imaging (when signing the informed consent form, a complete magnetic resonance safety review form is required); 15. Those who have installed ear hearing aids or any metal implants.

Design outcomes

Primary

MeasureTime frame
The positive and negative syndrome scale, PANSS;Scale for Assessment of Negative Symptoms, SANS;

Countries

China

Contacts

Public ContactYang Yongfeng

The Second Affiliated Hospital of Xinxiang Medical University

lxz123202202@163.com+86 158 3610 8413

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026